ClinicalTrials.gg
RecruitingNCT07704047Updated Jul 15, 2026

A Clinical Study of FT1 in Patients With Short Bowel Syndrome

A Phase 2 interventional study of FT1 and Placebo in Short Bowel Syndrome and SBS, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Short Bowel Syndrome with a site in China — 4 open to participants now, 6 under way, 2 of them phase 3. Short Bowel Syndrome · China.

Planned enrollment
10th of 10
8 · median 27
Started
2026
with 2 others
Phase 2
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
3 of 12
Chongqing Peg-Bio Biopharm Co., Ltd.

Among the 12 studies in Short Bowel Syndrome with a site in China, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 2, and was the 12th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

4 of the 12 studies in Short Bowel Syndrome with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Short Bowel Syndrome with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.

Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.

Participants will

  • Receive multiple injections of FT1 or placebo according to weight.
  • Visit the clinic for assessment.
Read the detailed description

In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, 8 adult SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.

Efficacy is evaluated through a 72 hour metabolic balance study conducted at baseline and at the end of each treatment cycle.

03

Conditions studied

  • Short Bowel Syndrome
  • SBS

Browse trials for

Keywords

  • short bowel syndrome
  • SBS
  • GLP-2
  • FT1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, male or female.
  • SBS secondary to surgical resection of the small intestine, screened for at least 12 months after pre intestinal resection surgery;
  • Stable weight before screening; For patients requiring parenteral support (PS), PS volume remained stable (with changes in volume or energy content\<25%) within 14 days prior to randomization;
  • Willing to undergo colonoscopy and remove polyps assessed by researchers to be at risk of cancer;
  • During the trial period, there were no plans to perform any major abdominal surgeries (such as intestinal resection exceeding 10% or surgeries that alter intestinal anatomy, such as stoma surgery);
  • During the baseline metabolic balance study, the average daily fecal wet rearrangement amount was ≥ 800g;

Exclusion criteria

Exclusion Criteria:

  • Having undergone major abdominal surgery (such as intestinal resection exceeding 10%) within the past 6 months prior to screening;
  • History of intestinal adhesions and/or chronic abdominal pain;
  • History of persistent radiation enteritis, celiac disease, diarrhea, etc;
  • Patients with malignant tumors within the past 5 years (excluding fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery);
  • History of gallstones in the past 3 years, except for those who have undergone cholecystectomy for gallstones; Acute cholecystitis or biliary obstruction related diseases that have not been treated within the previous month or during the screening period;
  • IBD patients with active inflammatory bowel disease (IBD), or requiring increased or altered therapy in the past 3 months, or receiving biologic therapy in the past 6 months;
  • Occurrence of central venous catheter-related bloodstream infections within 2 months prior to and during the screening period;
  • Patients diagnosed with decompensated heart failure ( grade III or above) and/or unstable angina and/or myocardial infarction from 6 months prior to screening until the first administration of the study drug;
  • Screening for individuals with rectal bleeding within the first 3 months;
  • Individuals with absorption instability caused by cystic fibrosis, untreated megacolon disease, or known DNA abnormalities (such as familial adenomatous polyposis, Fanconi syndrome);
  • Serious active, uncontrolled, untreated, acute onset systemic diseases (such as cardiovascular, respiratory, renal, infectious, endocrine, liver or central nervous system, etc.);
  • Pregnant or breastfeeding women.
  • The investigator believes the subject is unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    FT1

    FT1 will be administered subcutaneously once a week for 5 weeks during each treatment cycle.

    Drug: FT1

  • Placebo comparator
    FT1 Placebo

    FT1 Placebo will be administered subcutaneously once a week for 5 weeks during each treatment cycle.

    Drug: Placebo

Interventions

  • DrugFT1

    FT1 treatment, once weekly for 5 weeks

  • DrugPlacebo

    Placebo, once weekly for 5 weeks

06

What researchers measure

Primary outcomes

  1. Treatment-related Adverse Events

    To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, timing, seriousness, and relationship to study therapy after administration.

    Time frame: From the first administration to study completion, appropriately 5 months.

  2. Changes in fecal wet weight from baseline to the end of treatment

    The difference in changes in fecal wet weight in the 72-hour metabolic balance study after treatment compared to baseline

    Time frame: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)

Secondary outcomes

  1. Changes in urine volume from baseline to the end of treatment

    The difference in changes in urine volume in the 72-hour metabolic balance study after treatment compared to baseline

    Time frame: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)

  2. The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)

    Pharmacokinetic parameter

    Time frame: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)

  3. Maximum plasma concentration (Cmax)

    Pharmacokinetic parameter

    Time frame: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)

  4. Changes in L-citrulline levels in plasma

    Pharmacodynamic parameter

    Time frame: From Day 1 of the first cycle to the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Apr 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 15, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Apr 15, 2027
CompletionEst.
Apr 15, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07704047
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Apr 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Jing Sun
Contact
sunj@pegbiocq.com
+86-13983367811

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion